Standard BioTools Inc. Cost of Revenue
Standard BioTools Inc. (LAB) reported Cost of Revenue of $300.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2017-03-03.
Discontinued › Expense Statement › Cost of Sales
us-gaap:CostOfRevenue · last filed 2017-03-03
- Standard BioTools Inc. cost of revenue for fiscal 2016 was $300.00K, a 0.00% change from fiscal 2015.
- Standard BioTools Inc. cost of revenue for fiscal 2015 was $300.00K, a 0.00% change from fiscal 2014.
- Standard BioTools Inc. cost of revenue for fiscal 2014 was $300.00K, a 0.00% change from fiscal 2013.
- Standard BioTools Inc. cost of revenue for fiscal 2013 was $300.00K, a 0.00% change from fiscal 2012.
| Period end | Cost of Revenue 12 month |
|---|---|
| 2016-12-31 | $300.00K 10-K · filed 2017-03-03 |
| 2015-12-31 | $300.00K 10-K · filed 2017-03-03 |
| 2014-12-31 | $300.00K 10-K · filed 2017-03-03 |
| 2013-12-31 | $300.00K 10-K · filed 2016-02-29 |
| 2012-12-31 | $300.00K 10-K · filed 2015-02-26 |
| 2011-12-31 | $100.00K 10-K · filed 2014-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |